Buy & Sell iShares Core High Dividend ETF (HDV) – iShares Core High Dividend ETF Price Today
Aura AI Summary
Key Stats
- -Market Cap
- -Sector
- -5.74%3M Drawdown
- -Enterprise Value
- -Dividend Yield
- 100 daysTypical Hold Time
Over the past 52 weeks, iShares Core High Dividend ETF has traded between a low of $23.02 and a high of $28.2, highlighting its annual price range. Over the past three months, iShares Core High Dividend ETF has recorded a drawdown of -5.74%, reflecting recent price volatility. On average, investors hold iShares Core High Dividend ETF for approximately 100 days, indicating typical investor behavior on the platform.
About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Most Recent News
CBAK Energy unveils advanced LFP cylindrical batteries boosting Southeast Asia's electric mobility.
CBAK Energy Technology showcased its innovative lithium-ion and sodium-ion cylindrical batteries designed for Southeast Asia's electric two- and three-wheelers at Autotech & Accessories 2026. Their batteries feature long life, high reliability, and s...
WeRide and Renault deploy autonomous Robobus at Roland-Garros for third year, expanding night service.
WeRide and Renault Group continue their partnership by operating the autonomous Robobus shuttle service at the Roland-Garros tennis tournament for the third consecutive year. The service runs a 2.8 km route connecting key points around the stadium, o...
Eli Lilly's gene therapy VERVE-102 cuts LDL cholesterol by up to 62% with lasting effects.
Eli Lilly reported positive Phase 1b results for VERVE-102, a gene therapy that permanently silences the PCSK9 gene to reduce LDL cholesterol by up to 62%. The therapy showed sustained effects for up to 18 months and was well-tolerated with no seriou...